ERBB2 and carcinoma: The rate of human epidermal growth factor receptor 2 (HER2)-positive carcinomas was higher in patients with BCRL (n = 11, 15%) than in BCRL-negative (n = 26, 9%), albeit not statistically significant (Supplementary Table S1).